FDA Proposes Excluding BPC-157, KPV and MOTS-c From the 503A Bulks List

TheBrief

FDA materials propose keeping BPC-157, KPV and MOTS-c off the 503A Bulks List. As of September 2026, this remains a proposed regulatory position rather than a final exclusion. If the substances are ultimately not added to the list and no other qualifying basis applies, traditional 503A pharmacies would generally not be able to rely on the federal 503A exemption when compounding these peptides from bulk substances.

What the FDA materials recommend

The FDA has proposed that BPC-157 (free base and acetate), KPV (free base and acetate), and MOTS-c (free base and acetate) not be included on the 503A Bulks List. FDA reviewed the substances using criteria that include physical and chemical characterization, available evidence of effectiveness, safety concerns and historical use in compounding.

This is a regulatory evidence assessment, not a clinical trial. It does not produce a treatment effect estimate or prove that a peptide has no biological activity. Instead, FDA is assessing whether the available evidence supports allowing these bulk substances to be used by qualifying compounders under the 503A framework.

The distinction matters because these peptides have been promoted for a range of purposes, including wound healing, inflammatory conditions, gastrointestinal disorders, metabolic health and exercise-related outcomes. However, the FDA materials do not establish these peptides as approved treatments for those conditions, and the proposed uses reviewed by FDA differ by substance.

For BPC-157, FDA evaluated proposed use in ulcerative colitis and found limited human evidence for the proposed routes of administration. For KPV, the review focused on wound healing and inflammatory conditions, while the MOTS-c assessment considered uses including obesity and osteoporosis. FDA reported insufficient clinical evidence to evaluate effectiveness for the nominated uses of all three substances.

The current status is also important. The July 2026 Pharmacy Compounding Advisory Committee materials contain FDA proposals and committee proceedings, but an advisory committee recommendation is not itself a final regulation. Pharmacies and prescribers therefore need to distinguish the July meeting materials from the legally operative 503A list and any applicable FDA enforcement policy.

Why the 503A list is consequential

Section 503A creates exemptions from several federal requirements for qualifying drugs compounded by licensed pharmacists or physicians, generally for an identified individual patient based on a valid prescription. Among its conditions, a pharmacy using a bulk drug substance must have a qualifying basis for that ingredient.

In broad terms, the bulk substance must comply with an applicable United States Pharmacopeia or National Formulary monograph, be a component of an FDA-approved drug, or appear on the 503A Bulks List developed through the federal regulatory process. A patient-specific prescription does not independently override this ingredient requirement.

BPC-157, KPV and MOTS-c are not components of FDA-approved drug products. If they lack another qualifying basis and are excluded from the 503A list, a traditional pharmacy generally could not rely on Section 503A while preparing products from those bulk peptides. The resulting product would lose the statute’s key exemptions and could face federal requirements that ordinary compounded drugs are not positioned to meet, including new-drug approval, labeling and current good manufacturing practice provisions.

Exclusion would not convert the products into approved drugs, validate products already supplied or resolve questions under state pharmacy and medical-practice law. It also would not, by itself, answer whether an outsourcing facility could compound the same substance under Section 503B, which has a separate statutory framework and bulk-substance process.

Consequences for pharmacies and prescribers

Traditional compounding pharmacies would need to review whether they could continue accepting prescriptions, holding bulk inventory, preparing formulations or shipping affected products. Pharmacies relying on 503A could also face scrutiny from the FDA and state boards if they continued compounding from an ineligible bulk substance. Labels such as “research use only” would not necessarily resolve the problem when a product is actually prepared or distributed for human use.

The practical effect may extend beyond production. Pharmacies could have to cancel pending prescriptions, notify prescribers, revise formularies, address unused inventory and reassess advertising that describes these peptides as available compounded therapies. Because federal and state authorities have overlapping roles, the exact enforcement and licensing consequences could vary by jurisdiction and conduct.

For prescribers, exclusion would primarily affect access rather than directly create a new federal prohibition on writing a prescription. A prescription cannot, however, make a pharmacy’s otherwise noncompliant bulk compounding lawful. Clinicians who have recommended these products could therefore encounter interrupted supply, pharmacy refusals or patients turning to less transparent sellers outside conventional pharmacy channels.

That last possibility is a safety concern, not an argument for maintaining 503A access without adequate evidence. Products sold online or labeled for research may have uncertain identity, strength, purity and sterility. Injectable preparations add risks associated with contamination, endotoxins and administration. Peptides may also present unresolved risks related to immunogenicity, degradation products and biologic activity beyond the intended target.

Clinicians discussing prior or ongoing use should separate reported experiences from demonstrated efficacy. Improvement after an unapproved peptide does not establish causation, particularly when symptoms fluctuate, rehabilitation or other treatments occur simultaneously, and no adequate comparator is present. Adverse events and product-quality problems should be documented and reported through appropriate FDA and state channels.

Evidence gaps behind the recommendation

The FDA materials conclude that the evidence submitted or identified is insufficient to support inclusion. Laboratory and animal findings can identify biological activity, but they cannot establish clinical benefit, human dosing, long-term safety or the reliability of a compounded formulation. Small or uncontrolled human observations, where available, are also vulnerable to selection bias, placebo effects, incomplete adverse-event capture and confounding.

Important questions remain unresolved for each peptide: which clinical condition would be treated, whether a reproducible benefit exists, what exposure produces that benefit, and which short- and long-term harms should be monitored. Formulation-specific questions also matter because route, concentration, excipients, container systems and storage can change the quality and behavior of a peptide product.

Limitations: The FDA assessment is designed to inform a compounding-list decision, not to calculate a pooled treatment effect or issue a disease-specific clinical guideline. Its conclusions may also be updated if new evidence enters the record. The recommendation should therefore be read as a judgment about the evidence and regulatory criteria available at the time, not proof that every possible clinical effect is absent.

What happens next

The immediate policy question is whether the FDA completes the process required to exclude or decline to include the substances and how it applies any interim enforcement policy. Until then, pharmacies should distinguish a proposed or advisory position from a final, legally operative list decision.

If exclusion becomes effective, the clearest consequence is that customization would not cure the underlying eligibility problem. Changing the concentration, combining the peptide with another ingredient or preparing it for a named patient would not create a qualifying basis for use of the bulk substance.

The decision would also reinforce a broader boundary in compounding policy. Section 503A is intended to accommodate clinically necessary, patient-specific preparation; it is not an alternative approval pathway for introducing active ingredients whose safety, effectiveness and manufacturing controls have not been adequately established.

Questions clinicians ask

Can I still prescribe one of these peptides?

The FDA materials address whether traditional pharmacies may use the peptides as bulk ingredients under Section 503A, not professional licensure in a particular state. Even if writing a prescription is not categorically barred, that prescription cannot make an ineligible bulk substance lawful for a 503A pharmacy to compound.

Does a recommendation take effect immediately?

Not necessarily. FDA staff materials or an advisory committee recommendation are not the same as a final regulatory action. Clinicians and pharmacies should verify the current 503A list, relevant FDA enforcement policy and state requirements before deciding whether a particular preparation remains available.

Could a pharmacy compound the peptide for one named patient?

Naming an individual patient satisfies only one part of the 503A framework. The bulk ingredient must also meet the statute’s substance criteria, so a patient-specific prescription would not overcome final exclusion when the peptide has no other qualifying basis.

Are these peptides proven ineffective?

No. Insufficient evidence is not the same as definitive proof of no effect. It means the available evidence does not adequately establish clinical benefit and safety for the proposed uses, leaving regulators without the support needed to permit bulk compounding through this pathway.

References

1. Pharmacy Compounding Advisory Materials on BPC-157, KPV and MOTS-c — U.S. Food and Drug Administration, 2026 2. Compounding and the FDA: Questions and Answers — U.S. Food and Drug Administration, n.d. 3. Compounding Laws and Policies — U.S. Food and Drug Administration, n.d.